Bulletin from the Annual General Meeting of CellaVision AB (publ)
Kurs
-0,44%
Likviditet
1,42 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2026-02-05 | 07:30 | Bokslutskommuniké 2025 |
| 2025-11-06 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-07-18 | 07:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-06 | N/A | Årsstämma |
| 2025-04-29 | 07:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-06 | 07:30 | Bokslutskommuniké 2024 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-19 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-06 | - | X-dag ordinarie utdelning CEVI 2.25 SEK |
| 2024-05-03 | - | Årsstämma |
| 2024-05-03 | - | X-dag ordinarie utdelning CEVI 2.25 SEK |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-07 | - | Bokslutskommuniké 2023 |
| 2023-10-25 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-20 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-08 | - | X-dag ordinarie utdelning CEVI 2.25 SEK |
| 2023-05-05 | - | Årsstämma |
| 2023-05-05 | - | X-dag ordinarie utdelning CEVI 2.25 SEK |
| 2023-05-04 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-07 | - | Bokslutskommuniké 2022 |
| 2022-10-26 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-20 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | X-dag ordinarie utdelning CEVI 2.00 SEK |
| 2022-05-11 | - | Årsstämma |
| 2022-05-10 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-04 | - | Bokslutskommuniké 2021 |
| 2021-10-22 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-30 | - | X-dag ordinarie utdelning CEVI 0.75 SEK |
| 2021-04-29 | - | Årsstämma |
| 2021-04-28 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-04 | - | Bokslutskommuniké 2020 |
| 2020-10-23 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-16 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-17 | - | X-dag ordinarie utdelning CEVI 0.00 SEK |
| 2020-06-16 | - | Årsstämma |
| 2020-04-22 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-05 | - | Bokslutskommuniké 2019 |
| 2019-10-23 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-16 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-09 | - | X-dag ordinarie utdelning CEVI 1.50 SEK |
| 2019-05-08 | - | Årsstämma |
| 2019-05-07 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-07 | - | Bokslutskommuniké 2018 |
| 2018-10-23 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-19 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-07 | - | X-dag ordinarie utdelning CEVI 1.50 SEK |
| 2018-05-04 | - | Årsstämma |
| 2018-05-03 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-09 | - | Bokslutskommuniké 2017 |
| 2017-10-25 | - | Kvartalsrapport 2017-Q3 |
| 2017-07-18 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-08 | - | X-dag ordinarie utdelning CEVI 1.50 SEK |
| 2017-05-05 | - | Årsstämma |
| 2017-05-04 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-07 | - | Bokslutskommuniké 2016 |
| 2016-10-27 | - | Kvartalsrapport 2016-Q3 |
| 2016-07-15 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-06 | - | X-dag ordinarie utdelning CEVI 1.50 SEK |
| 2016-05-04 | - | Årsstämma |
| 2016-05-03 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-12 | - | Bokslutskommuniké 2015 |
| 2015-11-09 | - | Kvartalsrapport 2015-Q3 |
| 2015-07-17 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-07 | - | X-dag ordinarie utdelning CEVI 1.00 SEK |
| 2015-05-06 | - | Årsstämma |
| 2015-05-05 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-12 | - | Bokslutskommuniké 2014 |
| 2014-11-05 | - | Kvartalsrapport 2014-Q3 |
| 2014-07-18 | - | Kvartalsrapport 2014-Q2 |
| 2014-05-08 | - | X-dag ordinarie utdelning CEVI 0.50 SEK |
| 2014-05-07 | - | Årsstämma |
| 2014-05-06 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-13 | - | Bokslutskommuniké 2013 |
| 2013-10-24 | - | Kvartalsrapport 2013-Q3 |
| 2013-07-17 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-25 | - | X-dag ordinarie utdelning CEVI 0.40 SEK |
| 2013-04-24 | - | Årsstämma |
| 2013-04-24 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-14 | - | Bokslutskommuniké 2012 |
| 2012-10-26 | - | Kvartalsrapport 2012-Q3 |
| 2012-07-18 | - | Kvartalsrapport 2012-Q2 |
| 2012-05-24 | - | Kapitalmarknadsdag 2012 |
| 2012-05-03 | - | X-dag ordinarie utdelning CEVI 0.40 SEK |
| 2012-05-02 | - | Årsstämma |
| 2012-04-25 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-14 | - | Bokslutskommuniké 2011 |
| 2011-10-25 | - | Kvartalsrapport 2011-Q3 |
| 2011-07-15 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-27 | - | X-dag ordinarie utdelning CEVI 0.00 SEK |
| 2011-04-26 | - | Årsstämma |
| 2011-04-20 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-15 | - | Bokslutskommuniké 2010 |
| 2010-10-27 | - | Kvartalsrapport 2010-Q3 |
| 2010-07-16 | - | Kvartalsrapport 2010-Q2 |
| 2010-04-30 | - | X-dag ordinarie utdelning CEVI 0.00 SEK |
| 2010-04-29 | - | Kvartalsrapport 2010-Q1 |
| 2010-02-12 | - | Bokslutskommuniké 2009 |
| 2009-10-23 | - | Kvartalsrapport 2009-Q3 |
| 2009-07-15 | - | Kvartalsrapport 2009-Q2 |
| 2009-04-27 | - | Årsstämma |
| 2009-04-27 | - | Kvartalsrapport 2009-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
The following resolutions were passed at the Annual General Meeting (the “AGM”) of CellaVision AB (publ) (“CellaVision”) on 3 May 2024 in Lund.
Adoption of profit and loss account and balance sheet and discharge from liability
The AGM resolved to adopt the profit and loss account and the balance sheet as well as the consolidated profit and loss account and the consolidated balance sheet for the financial year 2023. Furthermore, the members of the Board of Directors and the CEO were discharged from liability for the financial year 2023.
Allocation of profit
The AGM resolved, in accordance with the Board of Directors’ proposal, on a dividend of SEK 2.25 per share with record date on 7 May 2024. The dividend is expected to be paid by Euroclear Sweden AB on 13 May 2024.
Board of Directors and auditor
The AGM resolved, in accordance with the Nomination committee’s proposal, on re-election of Mikael Worning, Christer Fåhraeus, Stefan Wolf, Ann-Charlotte Jarleryd and Louise Armstrong-Denby as Board members. Mikael Worning was also re-elected as the Chairman of the Board of Directors. The AGM resolved on re-election of the audit firm KPMG AB as auditor.
Furthermore, the AGM resolved on remuneration to the Board of Directors, remuneration to the auditor and additional remuneration for work in the Board’s committees in accordance with the Nomination committee’s proposal.
Nomination committee for the next Annual General Meeting
The AGM resolved, in accordance with the Nomination committee’s proposal, that the principles for appointing the Nomination committee which were adopted at the AGM in 2020 shall apply also for the AGM to be held in 2025.
Remuneration report
The AGM approved the Board of Directors’ remuneration report for the financial year 2023.
Contact
Adele Horn
Corporate Communications & Investor Relations Manager
Tel: + 46 46 460 26 04
www.cellavision.com
adele.horn@cellavision.com
About Us
CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 12 local market support organizations covering more than 40 countries. In 2023, sales were SEK 677 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com